CAJ | 학술논문

目的评价放疗联合表皮生长因子受体-酪氨酸激酶抑制剂(EGFR-TKI)靶向治疗Ⅳ期非小细胞肺癌(NSCLC)的疗效及安全性.方法 26例NSCLC患者.其中骨转移16例,脑转移10例.放疗部位包括肺原发灶及骨、脑转移灶,放疗期间同时服用吉非替尼250 mg每天1次,或厄洛替尼150 mg每天1次,直至肿瘤进展或出现不可耐受的副作用.结果所有患者在放疗期间均能完成放疗联合靶向治疗,12例患者出现腹泻,8例伴发呕吐,12例合并有皮疹.放疗前按美国东部肿瘤协作组(ECOG)评分平均为3分,放疗后为2分.骨转移局部控制率为93.8%(15/16),脑转移灶控制率为70.0%(7/10),肺部6个月局部控制率为84.6%(22/26).结论针对Ⅳ期NSCLC,姑息性放疗联合靶向治疗是有效而安全的治疗方法,其对生存时间的影响需要进一步观察.
목적 평개방료연합표피생장인자수체-락안산격매억제제(EGFR-TKI)파향치료Ⅳ기비소세포폐암(NSCLC)적료효급안전성.방법 26례NSCLC환자.기중골전이16례,뇌전이10례.방료부위포괄폐원발조급골、뇌전이조,방료기간동시복용길비체니250 mg매천1차,혹액락체니150 mg매천1차,직지종류진전혹출현불가내수적부작용.결과 소유환자재방료기간균능완성방료연합파향치료,12례환자출현복사,8례반발구토,12례합병유피진.방료전안미국동부종류협작조(ECOG)평분평균위3분,방료후위2분.골전이국부공제솔위93.8%(15/16),뇌전이조공제솔위70.0%(7/10),폐부6개월국부공제솔위84.6%(22/26).결론 침대Ⅳ기NSCLC,고식성방료연합파향치료시유효이안전적치료방법,기대생존시간적영향수요진일보관찰.
Objective To evaluate the efficacy and safety of radiation combined with targeted therapy of EGFR-TKI in the patients with stage IV non-small cell lung cancer ( NSCLC). Methods There were 17 female and 9 male patients with NSCLC enrolled into this study, which included 19 adenocarcinoma, 4 alveolar carcinoma and 3 uncertain carcinoma according to the iconography findings. Sixteen patients suffered from single or multiple bone metastasis,and 10 cases with brain metastasis. Gefitinib 250 mg or Erlotinib ISO mg per day were administrated during and after the process of radiation until the disease progressed. Results All patients had complete combined therapy, 12 of them suffered from diarrhea, 8 from emesia and 12 from erythra. The average score of ECOG improved from 3 to 2 after combined therapy. The bone metastasis control rate was 93.8% ,brain metastasis control rate was 70.0% , and the 6-month local lung lumps control rate was 84. 6%. Conclusion Palliative radiation combined with targeted therapy of EGFR-TKI is an effect and safe therapy for the patients with the stage IV of NSCLC, but the influence on survival shall be observed in further study.